Reshape Lifesciences Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Reshape Lifesciences Inc (RSLS) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Reshape Lifesciences Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 2M vs 190,560M combined for tracked competitors (0.0% combined share).
- Trending: Latest-quarter revenue run-rate is decelerating (-94.8% annualized vs trailing 12 months), vs holding steady (-1.3%) for its tracked peer group.
- Growth: Reshape Lifesciences Inc generated -97.2% revenue growth year over year in Q1 2026, vs 10.2% for its tracked competitors combined.
- Profitability: Its -3,119.6% net margin compares with 17.7% for the peer group.
- Peer revenue share: Reshape Lifesciences Inc accounted for 0.0% of combined revenue among its tracked peer group, up from 0.0% a year earlier.
- Peer differentiation: Revenue per employee of $0.13M compares with $0.49M for the peer group (0.3x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
RSLS Sales vs. its Competitors, Q1 2026
Reshape Lifesciences Inc reported revenue contraction of 97.16 % year on year in Q1 2026, below its competitors' combined revenue growth of 10.19 %.
With a net margin of -3,119.63 %, Reshape Lifesciences Inc reported lower profitability than its competitors (17.70 %).
Reshape Lifesciences Inc generated 0.00 % of the combined sales of its peer group, up from 0.00 % a year earlier.
Reshape Lifesciences Inc vs. its Competitors, Q1 2026
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Reshape Lifesciences Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Reshape Lifesciences Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (6) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Reshape Lifesciences Inc's competitor groups requires a Commercial License.
For context: the Major Pharmaceutical Preparations industry grew revenue 7.2% year over year, combined, vs -97.2% for Reshape Lifesciences Inc. Reshape Lifesciences Inc's share of combined industry revenue moved from 0.00% to 0.00%, a gain of 0.00 percentage points.
Reshape Lifesciences Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Reshape Lifesciences Inc | - | No | No | No |
| Competitors combined (17) | ||||
| High-Confidence Competitors (8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
RSLS Stock Performance relative to its Competitors
RSLS Stock Performance relative to High-Confidence Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Autonomix Medical Inc | 282.9% | Outperformed |
| 2 | Axogen inc | 282.9% | Outperformed |
| 3 | Johnson and Johnson | 282.9% | Outperformed |
| 4 | Becton Dickinson And Company | 282.9% | Outperformed |
| 5 | Orasure Technologies Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Reshape Lifesciences Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Reshape Lifesciences Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Reshape Lifesciences Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Reshape Lifesciences Inc | 26.23 | 2.42 |
| Johnson and Johnson | 663,585.20 | 97,929.00 |
| Intuitive Surgical Inc | 148,204.47 | 11,296.30 |
| Medtronic Plc | 115,016.45 | 37,542.00 |
| Boston Scientific Corporation | 65,053.43 | 20,997.00 |
| Becton Dickinson And Company | 50,582.30 | 20,840.00 |
| SUBTOTAL | 1,063,969.89 | 194,207.58 |
Sign in to see all competitors of Reshape Lifesciences Inc.
Sources: Reshape Lifesciences Inc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Reshape Lifesciences Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Reshape Lifesciences Inc's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Spatz Medical | Named by the company | 85% |
| Bausch Health | Named by the company | 85% |
| Johnson & Johnson | Named by the company | 85% |
| Almirall | Named by the company | 85% |
| Eyepoint Pharmaceuticals | Named by the company | 85% |
| Sun Pharma | Named by the company | 85% |
| Eli Lily | Named by the company | 85% |
| Medtronic plc | Named by the company | 85% |
| Apollo EndoSurgery, Inc. | Named by the company | 85% |
| Gelesis | Named by the company | 85% |
| Tarsier Pharma | Named by the company | 85% |
| Allurion Technologies Inc | Named by the company | 85% |
| Ethicon Inc. | Named by the company | 85% |
| Boston Scientific Corporation | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Reshape Lifesciences Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Reshape Lifesciences Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Reshape Lifesciences Inc | Pharmaceutical 100.00 % |
| Johnson and Johnson | Oncology 29.26 % |
| Medtronic Plc | CARDIOVASCULAR 38.34 % |
| Boston Scientific Corporation | Cardiovascular 67.31 % |
| Becton Dickinson And Company | Medical Essentials 34.94 % |
| Hologic Inc | Diagnostics 51.18 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Reshape Lifesciences Inc.
Reshape Lifesciences Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Reshape Lifesciences Inc | 26 | 134,512 | -565,757 |
| Johnson and Johnson | 663,585 | 695,518 | 149,411 |
| Intuitive Surgical Inc | 148,204 | 663,668 | 185,530 |
| Medtronic Plc | 115,016 | 395,179 | 55,463 |
| Boston Scientific Corporation | 65,053 | 355,881 | 62,186 |
| Becton Dickinson And Company | 50,582 | 289,444 | 13,069 |
| PEERS TOTAL | 1,063,944 | 489,749 | 86,888 |
Sign in to see all peers for Reshape Lifesciences Inc.
Reshape Lifesciences Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Johnson and Johnson | United States 57.42 % |
| Intuitive Surgical Inc | Geographic Distribution, Foreign 30.41 % |
| Medtronic Plc | United States 49.83 % |
| Boston Scientific Corporation | United States 63.11 % |
| Becton Dickinson And Company | United States 61.88 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Sign in to see all peers for Reshape Lifesciences Inc.
Reshape Lifesciences Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 498 companies in Reshape Lifesciences Inc's industry classification, broader than the peer set above. Market cap in millions of $.Reshape Lifesciences Inc ranks #0 of 498 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 827, indicating a unconcentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,062,533 | 19.39 % |
| 2 | Johnson and Johnson | 664,610 | 12.13 % |
| 3 | Beone Medicines Ltd | 545,679 | 9.96 % |
| 4 | Abbvie Inc | 467,633 | 8.54 % |
| 5 | Merck and Co Inc | 1,234 | 5.2% |
| 6 | Novartis Ag | 1,234 | 5.2% |
| 7 | Abbott Laboratories | 1,234 | 5.2% |
| 8 | Novo Nordisk A | 1,234 | 5.2% |
| 9 | Pfizer Inc | 1,234 | 5.2% |
| 10 | Vertex Pharmaceuticals Inc | 1,234 | 5.2% |
| 0 | Reshape Lifesciences Inc | 26 | 0.00 % |
Market cap and industry share for the rest of Reshape Lifesciences Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2025-08-14.
Reshape Lifesciences Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Major Pharmaceutical Preparations industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (341 companies).| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 54.30 % | 64.89 % (avg) | -10.6 pp |
| Operating Margin | - | industry median | - |
| EBITDA Margin | - | -7.21 % (avg) | - |
| Capital Intensity (Capex / Revenue) | - | 4.92 % (avg) | - |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Reshape Lifesciences Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | 71.66 % | -8.20 % | -63.95 % | -51.60 % | 20.36 % | -17.35 % | -23.95 % | -17.44 % |
| Operating Margin | -2,406.87 % | -406.16 % | -708.02 % | -752.64 % | -415.45 % | - | - | -88.54 % |
| Return on Invested Capital | -34.94 % | -100.17 % | -88.98 % | -79.22 % | -56.87 % | -102.11 % | -246.03 % | 67.54 % |
| P/E | - | - | - | - | - | - | - | 0.0x |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Reshape Lifesciences Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 827 (see Industry Market Structure & Concentration above) |
| Supplier Power | Not covered on this page | See Reshape Lifesciences Inc's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Reshape Lifesciences Inc's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Reshape Lifesciences Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Return on equity 1,802.7 points below the industry aggregate.
- Latest-quarter revenue run-rate is decelerating (-94.8% annualized vs trailing 12 months).
- Underperforming the U.S.A. 500 over the trailing 12 months.
Opportunities
No rule matched.
Threats
No rule matched.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Reshape Lifesciences Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Reshape Lifesciences Inc | 1.09 | 1.38 | - |
| Johnson and Johnson | 0.37 | 1.05 | 0.60 |
| Intuitive Surgical Inc | 1.43 | 4.80 | - |
| Medtronic Plc | 0.15 | 2.10 | 0.57 |
| Boston Scientific Corporation | 0.25 | 1.54 | 0.47 |
| Becton Dickinson And Company | 0.10 | 1.00 | 0.73 |
Sign in to see all peers for Reshape Lifesciences Inc.
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Reshape Lifesciences Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Reshape Lifesciences Inc | Q1 2026 | -96.3 % | - |
| Johnson and Johnson | Q2 2026 | +6.6 % | -0.1 % |
| Intuitive Surgical Inc | Q2 2026 | +29.3 % | +23.9 % |
| Medtronic Plc | Q2 2026 | +13.7 % | +41.3 % |
| Boston Scientific Corporation | Q2 2026 | +7.5 % | +13.8 % |
| Becton Dickinson And Company | Q2 2026 | +5.4 % | -34.3 % |
| PEERS TOTAL | +9.6 % | +5.7 % |
Sign in to see all peers for Reshape Lifesciences Inc.
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Reshape Lifesciences Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Reshape Lifesciences Inc | Q1 2026 | -96.9 % | - |
| Johnson and Johnson | Q2 2026 | +5.5 % | +26.7 % |
| Intuitive Surgical Inc | Q2 2026 | +13.4 % | -27.5 % |
| Medtronic Plc | Q2 2026 | +13.8 % | -0.2 % |
| Boston Scientific Corporation | Q2 2026 | -2.6 % | +24.2 % |
| Becton Dickinson And Company | Q2 2026 | +7.1 % | -12.8 % |
Sign in to see all peers for Reshape Lifesciences Inc.
Reshape Lifesciences Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Reshape Lifesciences Inc | - | - | - |
| Johnson and Johnson | 10.60% | 13.30% | 25.74% |
| Intuitive Surgical Inc | 15.63% | 17.11% | 17.82% |
| Medtronic Plc | 5.71% | 6.46% | 10.64% |
| Boston Scientific Corporation | 8.34% | 9.91% | 14.77% |
| Becton Dickinson And Company | 1.77% | 2.22% | 3.79% |
Sign in to see all peers for Reshape Lifesciences Inc.
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Reshape Lifesciences Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Reshape Lifesciences Inc | - | 10.83 |
| Johnson and Johnson | 31.48 | 6.78 |
| Intuitive Surgical Inc | 47.62 | 13.12 |
| Medtronic Plc | 263.24 | 3.06 |
| Boston Scientific Corporation | 17.88 | 3.10 |
| Becton Dickinson And Company | 55.54 | 2.43 |
| PEERS AVERAGE | 30.89 | 5.48 |
Sign in to see all peers for Reshape Lifesciences Inc.
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.